{
  "schema": "https://miscsubjects.com/schemas/jarticle.json",
  "status": "published",
  "slug": "peripheral-neuropathy",
  "title": "Peripheral neuropathy: the longest nerves fail first, so it starts in both feet",
  "kind": "accessible",
  "summary": "The longest nerves fail first, which is why this starts in both feet evenly. The B12 deficiency that long-term metformin causes, the five-year data showing individuals recover, the annual screening that costs almost nothing, and what the drugs actually buy.",
  "created": "2026-08-05T02:14:18.734Z",
  "body": [
    "It starts in the toes because they are furthest away. The nerves running to your feet are the longest cells in your body — a single one can run from the base of your spine to your big toe — and anything that starves or poisons a nerve hits the far end first, where the supply line is longest. That is why this begins in both feet at once rather than in one leg, why it creeps upward over months and years rather than jumping about, and why the hands only join in later, when the damage has climbed the legs to roughly the height of the knee.\n\nThat pattern is worth memorising, because it is what separates this from a pinched nerve. A pinched nerve in the back gives you one leg, in a stripe. This gives you both feet, evenly, in the shape of a sock.\n\n## The first job is not treating the pain. It is finding a cause you can reverse.\n\nMost of what gets written about neuropathy is about pain medication. That skips the step that matters more, because some causes of this are correctable and the nerves recover if you correct them early enough.\n\nThe one most often missed is vitamin B12, and the reason it is missed is that a common diabetes drug causes it. Metformin interferes with B12 absorption over years. A 2026 case report describes exactly what that looks like when nobody checks: nerve and spinal cord damage in someone on long-term metformin, which improved substantially over the following weeks once treated.",
    {
      "type": "source",
      "id": "s1"
    },
    "If you have been on metformin for years and have numb feet, the assumption that your neuropathy is diabetic is a coin flip, not a diagnosis. A B12 level is a cheap blood test and the treatment is injections.\n\nThe other reversible or modifiable causes worth ruling out before settling for pain control: alcohol intake, thyroid function, kidney function, and chemotherapy exposure.\n\n## Even long-standing nerve damage is not necessarily one-way\n\nThe standard belief — patient and clinician alike — is that once the nerves are damaged, the direction is downward and treatment is about slowing it. A 2026 study followed people with type 1 diabetes over five years and found something more useful than that.\n\nYes, overall prevalence rose over the five years. But individual people moved in both directions: some regressed to less severe disease, and some no longer met the criteria at all.",
    {
      "type": "source",
      "id": "s2"
    },
    "The authors' conclusion is the sentence to carry: continued intervention remains worthwhile well after the diagnosis has been made. Someone told years ago that they have neuropathy, who concluded that glucose control no longer mattered for their feet, was told something the data does not support.\n\n## Screening exists, it is cheap, and it is often not done\n\nThere is an agreed way to detect this before it becomes a foot problem, and it requires two instruments that cost almost nothing.",
    {
      "type": "source",
      "id": "s3"
    },
    "A monofilament — a nylon thread pressed against the sole until it buckles — and a tuning fork. Annually. If you have diabetes and cannot remember the last time somebody touched your feet with either, that is a reasonable thing to ask for by name.\n\nThe reason to insist is in the numbers on what happens when nobody checks. In a 2026 study of people over 60 with diabetes, peripheral neuropathy raised the odds of being in the at-risk foot category by roughly ninefold.",
    {
      "type": "source",
      "id": "s4"
    },
    "Ninefold. Not the pain — the foot. Numbness means injuries do not announce themselves, and the sequence that ends in amputation usually starts with something the person never felt.\n\n## What the drugs actually do, and which one first\n\nBe clear about what these are for: they reduce pain. None of them repairs a nerve. A 2026 review states the position plainly — treatment of the underlying nerve damage remains limited, and studies of causal therapy have produced conflicting results, so most treatment is glucose control plus symptom management.",
    {
      "type": "source",
      "id": "s5"
    },
    "Within symptom management, there is a real head-to-head answer. A trial comparing the first-line drugs found pregabalin better than amitriptyline and duloxetine, and about the same as gabapentin.",
    {
      "type": "source",
      "id": "s6"
    },
    "The same trial counted where the side effects landed: the duloxetine arm produced the most.\n\nBetween the two that came out on top, a 2024 pooled analysis separates them further: pregabalin worked better and faster than gabapentin, and the people taking it used fewer opioids and had fewer adverse events.",
    {
      "type": "source",
      "id": "s7"
    },
    "Note the contrast with nerve pain from a compressed root in the back, where these same drugs have repeatedly failed to beat placebo. That is not a contradiction. Pain from a mechanically squeezed nerve root and pain from diffusely damaged small nerve fibres are different problems that share a word, and evidence does not transfer between them. A drug can be a reasonable first choice here and close to useless for sciatica.\n\n## Ten people with numb feet\n\nTen people develop numbness in both feet. Most will be told it is diabetic neuropathy. In some of them — nobody can say how many without checking — the treatable driver is a B12 level lowered by years of metformin, and it will not be found unless someone looks. Over five years, the overall picture in a group like this gets worse, while individuals move in both directions and some improve. Of the ten, the ones who get a monofilament and a tuning fork on their feet once a year are the ones whose foot injuries get caught while they are still small, and the risk they are being screened for is roughly ninefold. Everyone offered a drug should understand they are buying pain relief and not nerve repair.\n\n## Why the compound argument belongs on a different page\n\nNo repair peptide has randomised human trial evidence in peripheral neuropathy. There is one compound with genuinely relevant human trial history in nerve conditions, but that argument belongs on a page whose title names both it and this condition, with its evidence tier stated — writing it here would turn a page about a condition into a case for a product, which is the failure this site is built to avoid. The operator of this site has a commercial interest in compounds of that kind, which is why this page states the absence rather than working around it.\n\n## What to ask for at the next appointment\n\n1. **Check the pattern.** Both feet, evenly, creeping upward. One leg in a stripe is a different problem and belongs in a different article.\n2. **Get B12 measured — particularly if you take metformin.** It is a blood test, the deficiency is common on long-term metformin, and treating it early is the difference between recovery and permanence.\n3. **Rule out the other correctable drivers.** Thyroid, kidney function, alcohol intake.\n4. **Ask for the monofilament and the tuning fork by name, once a year.** Neuropathy raises at-risk foot odds roughly ninefold, and the screening costs almost nothing.\n5. **Do not accept that it is too late for glucose control to matter.** Over five years, individuals regressed to less severe disease and some no longer met the criteria.\n6. **If you need a drug, know what it is buying.** Pain relief, not nerve repair — and in the head-to-head evidence pregabalin came out ahead of amitriptyline and duloxetine, with duloxetine producing the most side effects."
  ],
  "facts": {
    "converted_from": "markdown",
    "original_updated": "2026-08-05T03:13:21.220Z",
    "register": "accessible",
    "category": null
  },
  "model": "unattributed",
  "sources": [
    {
      "id": "s1",
      "type": "pubmed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42035456/",
      "external_id": "42035456",
      "pmid": "42035456",
      "title": "Metformin-Associated Functional Vitamin B12 Deficiency Presenting as Subacute Combined Degeneration in a 57-Year-Old Man With Diabetes Mellitus",
      "quote": "CONCLUSIONS This case of metformin-associated cobalamin deficiency with subacute combined degeneration of the spinal cord highlights the importance of monitoring vitamin B12 status and neurological sy",
      "summary": "American Journal of Case Reports 2026: nerve and spinal cord damage from B12 deficiency caused by long-term metformin, which improved substantially within weeks of treatment. The commonest missed reversible cause in people who already have a diabetes label.",
      "author": "Zhang R, Gou L et al.",
      "publisher": "The American journal of case reports",
      "date": "2026",
      "tag": "Case report",
      "accessed_at": "2026-08-05T01:41:58.243Z",
      "prev": "genesis",
      "hash": "09d9d89b36f25d0a23b4b4bf379e607925240122d1562218a2b517205ca498e5",
      "quote_sha256": "c43ea48b3d8ca720cd360d9fdc263c579684800fceaa7c60f3026cf586f4b7cf"
    },
    {
      "id": "s2",
      "type": "pubmed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42043615/",
      "external_id": "42043615",
      "pmid": "42043615",
      "title": "Heterogeneous course of diabetic polyneuropathy in type 1 diabetes over 5 years: is regression possible?",
      "quote": "CONCLUSIONS: Over 5 years the overall prevalence of DPN increased; however, regression to less severe DPN or complete absence of DPN occurred.",
      "summary": "Endocrine 2026: five years of follow-up in type 1 diabetes. Prevalence rose across the group while individuals moved both ways — some to less severe disease, some out of the diagnosis entirely. The authors conclude continued intervention remains worthwhile well after diagnosis.",
      "author": "Pertile P, D'Ippolito I et al.",
      "publisher": "Endocrine",
      "date": "2026",
      "tag": "Cohort study",
      "accessed_at": "2026-08-05T01:41:58.243Z",
      "prev": "09d9d89b36f25d0a23b4b4bf379e607925240122d1562218a2b517205ca498e5",
      "hash": "e8442138d5b22942839d89ec1f45729f2cfb331d862835a6740f42b77d4cdfb6",
      "quote_sha256": "bd932117f7c8da9d6e574af8767e81f6f871e684d9ed91a4ed047138a904a402"
    },
    {
      "id": "s3",
      "type": "pubmed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41364419/",
      "external_id": "41364419",
      "pmid": "41364419",
      "title": "Diabetic Peripheral Neuropathy: New Diagnostics and Treatment Perspectives",
      "quote": "Every diabetes clinic should perform annual screening for DPN to identify the risk of diabetic foot disease using a monofilament and tuning fork (or biothesiometer).",
      "summary": "Drugs & Aging 2026: the agreed screening method, requiring two instruments that cost almost nothing, done once a year.",
      "author": "Dubský M, Sojáková D et al.",
      "publisher": "Drugs & aging",
      "date": "2026",
      "tag": "Review",
      "accessed_at": "2026-08-05T01:41:58.243Z",
      "prev": "e8442138d5b22942839d89ec1f45729f2cfb331d862835a6740f42b77d4cdfb6",
      "hash": "ec8d701cceaf0e41835fb9e142ef47221b5781ee2383f4ba0821cb25243a9bd8",
      "quote_sha256": "02dad63feb7d6dca31c488375902fbaadcf92aaddfca3680ce7b88dfeaeda920"
    },
    {
      "id": "s4",
      "type": "pubmed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42063783/",
      "external_id": "42063783",
      "pmid": "42063783",
      "title": "Risk factors for diabetic at-risk foot disease among the diabetes over 60 years old: a cross-sectional study",
      "quote": "Notably, peripheral neuropathy (PN) significantly increased the probability of at-risk foot condition by approximately 882.9% (OR = 9.829, 95% CI: 4.607-20.969, p ConclusionA high percentage of people",
      "summary": "Frontiers in Medicine 2026: in people over 60 with diabetes, neuropathy raised the odds of an at-risk foot roughly ninefold. Numbness means an injury does not announce itself.",
      "author": "Wu M, Xiao S et al.",
      "publisher": "Frontiers in medicine",
      "date": "2026",
      "tag": "Cross-sectional study",
      "accessed_at": "2026-08-05T01:41:58.243Z",
      "prev": "ec8d701cceaf0e41835fb9e142ef47221b5781ee2383f4ba0821cb25243a9bd8",
      "hash": "d8bdae4fbe43c52bd9298579b8c19da4ecac68dd8b8667758c89b43264e65b1c",
      "quote_sha256": "e13be6ed467830764a3df261a07ecadf3f4ab2e12641b9fec672a3fb39b668f1"
    },
    {
      "id": "s5",
      "type": "pubmed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41364419/",
      "external_id": "41364419",
      "pmid": "41364419",
      "title": "Diabetic Peripheral Neuropathy: New Diagnostics and Treatment Perspectives",
      "quote": "The treatment of diabetic neuropathy remains limited, as studies on causal therapy have shown conflicting results.",
      "summary": "The same review on what the drugs are for: treatment of the underlying nerve damage remains limited, so most of it is glucose control plus symptom management.",
      "author": "Dubský M, Sojáková D et al.",
      "publisher": "Drugs & aging",
      "date": "2026",
      "tag": "Review",
      "accessed_at": "2026-08-05T01:41:58.243Z",
      "prev": "d8bdae4fbe43c52bd9298579b8c19da4ecac68dd8b8667758c89b43264e65b1c",
      "hash": "59e5071c098897d89b6e144673de4d5cd65add139925cc4f85892bc69a88b69e",
      "quote_sha256": "66ae50bfce116c26f28cb2f0554d3a58fad0904ae1b81e1613a2ce41b9ddf60c"
    },
    {
      "id": "s6",
      "type": "pubmed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/39544662/",
      "external_id": "39544662",
      "pmid": "39544662",
      "title": "Evaluation of Effectiveness and Safety of Firstline Drugs Used in the Treatment of Peripheral Neuropathy Among Elderly Population-A Randomised, Open-label, Active Comparator Study",
      "quote": "Pregabalin was superior to amitriptyline and duloxetine, whereas it was comparable to gabapentin in effectiveness.",
      "summary": "Annals of Neurosciences 2026: a head-to-head of the first-line drugs. The same trial counted 14 adverse events in total, the largest share of them in the duloxetine arm.",
      "author": "Balasundaram MK, Kannauje PK et al.",
      "publisher": "Annals of neurosciences",
      "date": "2026",
      "tag": "Randomised comparison",
      "accessed_at": "2026-08-05T01:41:58.243Z",
      "prev": "59e5071c098897d89b6e144673de4d5cd65add139925cc4f85892bc69a88b69e",
      "hash": "e1a7633c36d52a610cc18dcbf4a6f313cb6b58caa15e6bcc586074c617c14c81",
      "quote_sha256": "33b5de75f4d43ee86b783f52912f8fdb451bf198060061477e797e737f63a364"
    },
    {
      "id": "s7",
      "type": "pubmed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/39839199/",
      "external_id": "39839199",
      "pmid": "39839199",
      "title": "Pregabalin vs. gabapentin in the treatment of neuropathic pain: a comprehensive systematic review and meta-analysis of effectiveness and safety",
      "quote": "In conclusion, pregabalin demonstrated superior and faster efficacy in alleviating neuropathic pain than gabapentin did.",
      "summary": "Frontiers in Pain Research 2024: pooled analysis separating the two drugs that came out on top — pregabalin worked better and sooner, with lower opioid use and fewer adverse events.",
      "author": "Mayoral V, Galvez R et al.",
      "publisher": "Frontiers in pain research (Lausanne, Switzerland)",
      "date": "2024",
      "tag": "Meta-analysis",
      "accessed_at": "2026-08-05T01:41:58.243Z",
      "prev": "e1a7633c36d52a610cc18dcbf4a6f313cb6b58caa15e6bcc586074c617c14c81",
      "hash": "4c66a419a7df719c3bdb943b4b4133ccdc9d3dc86ce615ea235355d830f90160",
      "quote_sha256": "b287b3db252bf43ef003f1bdaaef1703f5ef08c3fb9f953df1dddf8573510c82"
    }
  ],
  "type": "article",
  "updated": "2026-10-08T11:31:43.221Z",
  "version": 1,
  "hash": "5ba2b59e6d9515798c4035ab9ba16e062afc96a41defe90b4b9fbbe4be52161f",
  "styling": {
    "scope": "shared",
    "how": "no value on the page is set by hand: each comes from this theme, and each theme value becomes the CSS variable named beside it. PATCH https://miscsubjects.com/api/jarticles/theme changes them.",
    "widget_style": {
      "what": "every widget may carry style: {…}; these are the only keys it reads",
      "rotate": "degrees, a number",
      "offset_x": "pixels, a number",
      "offset_y": "pixels, a number",
      "pulse": "true to pulse"
    },
    "theme": {
      "color": {
        "page_bg": "#f5f5f7",
        "sheet_bg": "#ffffff",
        "ink": "#1d1d1f",
        "soft": "#424245",
        "muted": "#6e6e73",
        "dim": "#86868b",
        "line": "#d2d2d7",
        "accent": "#0071e3",
        "accent_soft": "rgba(0,113,227,0.08)",
        "link": "#0066cc",
        "selection": "rgba(0,113,227,0.18)",
        "widget_bg": "#f5f5f7",
        "widget_border": "#d2d2d7",
        "card_bg": "#ffffff",
        "code_bg": "#f5f5f7",
        "json_bg": "#161b19",
        "json_ink": "#e6e1d4",
        "json_key": "#7fd3c3",
        "json_string": "#e9c46a",
        "json_number": "#f4a261",
        "json_bool": "#c792ea",
        "json_null": "#928d7e",
        "json_punct": "#6b6759",
        "json_bar": "#0e1512",
        "kind_badge_bg": "#0e6e60",
        "kind_badge_ink": "#ffffff"
      },
      "color_dark": {
        "page_bg": "#000000",
        "sheet_bg": "#1d1d1f",
        "ink": "#f5f5f7",
        "soft": "#d2d2d7",
        "muted": "#a1a1a6",
        "dim": "#86868b",
        "line": "#424245",
        "accent": "#2997ff",
        "accent_soft": "rgba(41,151,255,0.12)",
        "link": "#2997ff",
        "selection": "rgba(41,151,255,0.25)",
        "widget_bg": "#2c2c2e",
        "widget_border": "#424245",
        "card_bg": "#1d1d1f",
        "code_bg": "#2c2c2e",
        "json_bg": "#0a0d0c",
        "json_ink": "#e6e1d4",
        "json_key": "#7fd3c3",
        "json_string": "#e9c46a",
        "json_number": "#f4a261",
        "json_bool": "#c792ea",
        "json_null": "#757062",
        "json_punct": "#5d665f",
        "json_bar": "#060807",
        "kind_badge_bg": "#4fc1ab",
        "kind_badge_ink": "#0b0f0d"
      },
      "font": {
        "display": "-apple-system,BlinkMacSystemFont,\"SF Pro Display\",\"SF Pro Text\",\"Helvetica Neue\",Helvetica,Arial,sans-serif",
        "body": "-apple-system,BlinkMacSystemFont,\"SF Pro Display\",\"SF Pro Text\",\"Helvetica Neue\",Helvetica,Arial,sans-serif",
        "mono": "ui-monospace,SFMono-Regular,\"SF Mono\",Menlo,Consolas,monospace",
        "google_fonts": ""
      },
      "size": {
        "body": "17px",
        "small": "17px",
        "eye": "17px",
        "lead": "17px",
        "h1": "52px",
        "h2": "34px",
        "h3": "22px",
        "byline": "17px",
        "h1_measure": "none",
        "code": "17px",
        "json": "17px",
        "widget_title": "17px"
      },
      "leading": {
        "body": "1.7",
        "head": "1.18",
        "lead": "1.5",
        "json": "1.6"
      },
      "weight": {
        "display": "700",
        "head": "700",
        "body": "400",
        "strong": "700",
        "eye": "700"
      },
      "tracking": {
        "eye": "0.14em",
        "display": "-0.03em",
        "body": "-0.006em",
        "badge": "0.08em"
      },
      "layout": {
        "sheet_width": "1000px",
        "text_width": "880px",
        "gutter": "16px",
        "sheet_padding": "56px 64px 64px",
        "sheet_padding_mobile": "24px 18px 40px",
        "sheet_margin": "28px auto 72px",
        "block_gap": "1.15em",
        "widget_gap": "28px",
        "grid_gap": "14px"
      },
      "border": {
        "sheet": "0px solid",
        "sheet_radius": "30px",
        "widget": "1px solid",
        "widget_radius": "24px",
        "card_radius": "24px",
        "badge_radius": "999px",
        "rule": "1px solid",
        "code_radius": "18px",
        "accent_bar": "3px"
      },
      "shadow": {
        "sheet": "0 1px 1px rgba(0,0,0,.02),0 6px 26px rgba(0,0,0,.05)",
        "widget": "none",
        "card_hover": "0 10px 28px -16px rgba(28,27,23,0.35)"
      },
      "motion": {
        "hover": "160ms ease"
      }
    }
  },
  "page": "https://miscsubjects.com/a/peripheral-neuropathy",
  "json": "https://miscsubjects.com/a/peripheral-neuropathy.json",
  "markdown": "https://miscsubjects.com/a/peripheral-neuropathy.md",
  "theme": "https://miscsubjects.com/article-theme.json",
  "calls": [
    {
      "what": "this article as a page (no key)",
      "method": "GET",
      "url": "https://miscsubjects.com/a/peripheral-neuropathy",
      "headers": {}
    },
    {
      "what": "this article as its object (no key)",
      "method": "GET",
      "url": "https://miscsubjects.com/a/peripheral-neuropathy.json",
      "headers": {}
    },
    {
      "what": "this article as Markdown (no key)",
      "method": "GET",
      "url": "https://miscsubjects.com/a/peripheral-neuropathy.md",
      "headers": {}
    },
    {
      "what": "the object with its hash, drafts too",
      "method": "GET",
      "url": "https://miscsubjects.com/api/jarticles/peripheral-neuropathy",
      "headers": {
        "x-sheets-key": "$(cat /Users/cyrusmassoumi/.misc-sheets-key)"
      }
    },
    {
      "what": "one piece and that piece’s hash",
      "method": "GET",
      "url": "https://miscsubjects.com/api/jarticles/peripheral-neuropathy/at?path=facts",
      "headers": {
        "x-sheets-key": "$(cat /Users/cyrusmassoumi/.misc-sheets-key)"
      }
    },
    {
      "what": "grep: every key or value that matches, with the path to change it",
      "method": "GET",
      "url": "https://miscsubjects.com/api/jarticles/peripheral-neuropathy/grep?q=owner",
      "headers": {
        "x-sheets-key": "$(cat /Users/cyrusmassoumi/.misc-sheets-key)"
      }
    },
    {
      "what": "change pieces (set, merge, delete, append, insert, move); if-match is the hash",
      "method": "PATCH",
      "url": "https://miscsubjects.com/api/jarticles/peripheral-neuropathy",
      "headers": {
        "x-sheets-key": "$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
        "content-type": "application/json",
        "if-match": "<hash from the read>"
      },
      "body": {
        "ops": [
          {
            "op": "set",
            "path": "facts.example",
            "value": 1
          }
        ]
      }
    },
    {
      "what": "replace the whole object",
      "method": "PUT",
      "url": "https://miscsubjects.com/api/jarticles/peripheral-neuropathy",
      "headers": {
        "x-sheets-key": "$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
        "content-type": "application/json",
        "if-match": "<hash>"
      },
      "body": {
        "slug": "peripheral-neuropathy",
        "title": "…"
      }
    },
    {
      "what": "fetch every source, hash what came back and check the quote is in it",
      "method": "POST",
      "url": "https://miscsubjects.com/api/jarticles/peripheral-neuropathy/verify",
      "headers": {
        "x-sheets-key": "$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
        "content-type": "application/json"
      },
      "body": {}
    },
    {
      "what": "an Obsidian-style command",
      "method": "POST",
      "url": "https://miscsubjects.com/api/jarticles/cli",
      "headers": {
        "x-sheets-key": "$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
        "content-type": "application/json"
      },
      "body": {
        "command": "backlinks",
        "file": "peripheral-neuropathy"
      }
    }
  ]
}